Active, not recruitingPhase 2NCT05861453
Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease
Studying Sickle cell anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Afimmune
- Intervention
- Epeleuton(drug)
- Enrollment
- 30 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (18)
- University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States
- New England Sickle Cell Institute, UConn Health, Farmington, Connecticut, United States
- Medstar Health, Washington D.C., District of Columbia, United States
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta at Hughes Spalding, Atlanta, Georgia, United States
- Emory University - Georgia Comprehensive Sickle Cell Center, Atlanta, Georgia, United States
- Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta at Arthur M. Blank Hospital, Atlanta, Georgia, United States
- UI Health Sickle Cell Center, Chicago, Illinois, United States
- The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
- The Center for Cancer and Blood Disorders, A Division of American Oncology Partners, PA, Bethesda, Maryland, United States
- Kaiser Permanente Mid-Atlantic States, Largo, Maryland, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Robert Wood Johnson Medical School Rutgers, New Brunswick, New Jersey, United States
- Newark Beth Israel Medical Center, Newark, New Jersey, United States
- Jacobi Medical Center, The Bronx, New York, United States
- UNC Health, Chapel Hill, North Carolina, United States
- +3 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05861453 on ClinicalTrials.govOther trials for Sickle cell anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07369024Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young AdultsMohsen Saidinejad
- RECRUITINGNCT07373639A Long-term Follow-up Study in Patients Who Received BEAM-101Beam Therapeutics Inc.
- RECRUITINGNANCT07402811Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell DiseaseUniversity of Illinois at Chicago
- RECRUITINGPHASE1NCT06647979Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesDaniel Bauer
- RECRUITINGNANCT06555939Promoting Resilience Among Adolescents and Young Adults With Sickle Cell DiseaseBoston Children's Hospital
- RECRUITINGPHASE3NCT06975865The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseSanofi
- RECRUITINGNCT06944067Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell DiseaseNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT06923111PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]Nova Laboratories Limited